Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Non-Current Deffered Revenue (2016 - 2024)

Akebia Therapeutics has reported Non-Current Deffered Revenue over the past 10 years, most recently at $43.3 million for Q1 2024.

  • Quarterly Non-Current Deffered Revenue changed 0.0% to $43.3 million in Q1 2024 from the year-ago period, while the trailing twelve-month figure was $43.3 million through Mar 2024, changed 0.0% year-over-year, with the annual reading at $43.3 million for FY2023, 0.0% changed from the prior year.
  • Non-Current Deffered Revenue was $43.3 million for Q1 2024 at Akebia Therapeutics, roughly flat from $43.3 million in the prior quarter.
  • Over five years, Non-Current Deffered Revenue peaked at $65.4 million in Q1 2022 and troughed at $16.6 million in Q2 2021.
  • The 5-year median for Non-Current Deffered Revenue is $43.3 million (2022), against an average of $37.3 million.
  • Year-over-year, Non-Current Deffered Revenue plummeted 54.91% in 2021 and then skyrocketed 238.65% in 2022.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $25.3 million in 2020, then fell by 15.27% to $21.5 million in 2021, then soared by 101.62% to $43.3 million in 2022, then changed by 0.0% to $43.3 million in 2023, then changed by 0.0% to $43.3 million in 2024.
  • Per Business Quant, the three most recent readings for AKBA's Non-Current Deffered Revenue are $43.3 million (Q1 2024), $43.3 million (Q4 2023), and $43.3 million (Q3 2023).